Plasma microRNAs as potential biomarkers for non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death. Developing minimally invasive techniques that can diagnose NSCLC, particularly at an early stage, may improve its outcome. Using microarray platforms, we previously identified 12 microRNAs (miRNAs) the aberrant expressions of which in primary lung tumors are associated with early-stage NSCLC. Here, we extend our previous research by investigating whether the miRNAs could be used as potential plasma biomarkers for NSCLC. We initially validated expressions of the miRNAs in paired lung tumor tissues and plasma specimens from 28 stage I NSCLC patients by real-time quantitative reverse transcription PCR, and then evaluated diagnostic value of the plasma miRNAs in a cohort of 58 NSCLC patients and 29 healthy individuals. The altered miRNA expressions were reproducibly confirmed in the tumor tissues. The miRNAs were stably present and reliably measurable in plasma. Of the 12 miRNAs, five displayed significant concordance of the expression levels in plasma and the corresponding tumor tissues (all r>0.850, all P<0.05). A logistic regression model with the best prediction was defined on the basis of the four genes (miRNA-21, -126, -210, and 486-5p), yielding 86.22% sensitivity and 96.55% specificity in distinguishing NSCLC patients from the healthy controls. Furthermore, the panel of miRNAs produced 73.33% sensitivity and 96.55% specificity in identifying stage I NSCLC patients. In addition, the genes have higher sensitivity (91.67%) in diagnosis of lung adenocarcinomas compared with squamous cell carcinomas (82.35%) (P<0.05). Altered expressions of the miRNAs in plasma would provide potential blood-based biomarkers for NSCLC.

[1]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[2]  M. Tan,et al.  Regularized (bridge) logistic regression for variable selection based on ROC criterion , 2009 .

[3]  Gideon Rechavi,et al.  Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Jiang,et al.  Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers , 2010, Modern Pathology.

[5]  X. Yao,et al.  Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy , 2011, The Prostate.

[6]  Feng Jiang,et al.  Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers , 2010, International journal of cancer.

[7]  S. Volinia,et al.  Non-coding RNAs: a key to future personalized molecular therapy? , 2010, Genome Medicine.

[8]  A. Gazdar,et al.  Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  P. Platzer,et al.  Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. , 2008, American journal of human genetics.

[10]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[11]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[12]  M. Pepe.  The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[13]  John W M Martens,et al.  Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.

[14]  Lori E. Dodd,et al.  Partial AUC Estimation and Regression , 2003, Biometrics.

[15]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[16]  Feng-jun Wang,et al.  Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. , 2010, Gynecologic oncology.

[17]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[18]  L. Buscail,et al.  MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. , 2010, Clinical chemistry.

[19]  Israel Steinfeld,et al.  Novel Rank-Based Statistical Methods Reveal MicroRNAs with Differential Expression in Multiple Cancer Types , 2009, PloS one.

[20]  S. Belinsky,et al.  Gene-promoter hypermethylation as a biomarker in lung cancer , 2004, Nature Reviews Cancer.

[21]  Ricky T. Tong,et al.  Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. , 2009, Molecular cell.

[22]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[23]  J. Minna,et al.  Focus on lung cancer. , 2002, Cancer cell.

[24]  Hong Peng,et al.  Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. , 2010, Lung cancer.

[25]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Tao Jiang,et al.  The role of microRNA in human lung squamous cell carcinoma. , 2010, Cancer genetics and cytogenetics.

[27]  Zhaohui Huang,et al.  Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer , 2010, International journal of cancer.

[28]  H. Sahai,et al.  Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review. , 1996, Statistics in medicine.

[29]  S. Knudsen,et al.  Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. , 2010, Cancer research.

[30]  Jianfang Li,et al.  miR-126 functions as a tumour suppressor in human gastric cancer. , 2010, Cancer letters.

[31]  Shuomin Zhu,et al.  MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)* , 2007, Journal of Biological Chemistry.

[32]  Ann M. Killary,et al.  MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease , 2009, Cancer Prevention Research.

[33]  V. Ambros.  MicroRNA Pathways in Flies and Worms Growth, Death, Fat, Stress, and Timing , 2003, Cell.

[34]  W. C. Ball,et al.  Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. , 2015, The American review of respiratory disease.

[35]  R. Marks,et al.  Squamous cell carcinoma , 1996, The Lancet.

[36]  R. Berger,et al.  Bone marrow graft of a Fanconi's anemia patient. Cytogenetic study , 1980 .

[37]  Douglas C McCrory,et al.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence. , 2003, Chest.

[38]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[40]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[41]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.